An interventional study of Mixed test meal and Biological sampling in Obesity (BMI>30), Immune Abnormalities and Low-grade Inflammation, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Not yet recruiting at 4 sites in 3 countries. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 476 studies in Obesity with a site in France — 112 open to participants now, 128 under way, 25 of them phase 3. Obesity · France.
Among the 476 studies in Obesity with a site in France, this one is the 111th largest by planned enrollment of the 355 interventional ones that give a count, is one of 30 that started in 2026, is one of 259 with no phase, reaches primary completion later than 97 of the 127 other live ones, and was the 472nd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →112 of the 476 studies in Obesity with a site in France are open now. Recruiting first, the newest first:
Nantes University Hospital · Sites in France
Ages 18+
Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques · Sites in France
Ages 50–75
AstraZeneca · Sites in France, United States, Argentina and 13 more countries
Ages 18+
Novo Nordisk A/S · Sites in France, United States, Belgium and 7 more countries
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18–75
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 40 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
476 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 21 · Phase 3 61 · Phase 4 14
First in 2001; this study’s year is marked. 30 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 168 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 80 across the 355 interventional studies, 133 across the 121 observational. Of the 295 that completed or were terminated, 16 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 476 have an industry lead sponsor. The 10 most frequent:
Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.
Institut National de la Santé Et de la Recherche Médicale, France has 9 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
31 of the studies in Obesity with a site in France that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT03516968Phase 3Hospices Civils de LyonMonthly Boluses Versus Daily Doses for Correcting Blood Vitamin D Deficit in Obese Children and Adolescents | 2027-03 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
Add all 31 to your calendar (.ics) → With an account.
Among the 476 studies in Obesity with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obesity is a complex health condition defined by the World Health Organization (WHO) as an excess of body weight that may be harmful to health. It leads to other diseases such as type 2 diabetes or cardiovascular diseases, commonly referred to as "co-morbidities." Among these, it is known that obesity increases the risk of developing infectious diseases and of these diseases progressing to severe stages.
During the COVID-19 pandemic and the 2009 H1N1 influenza epidemic, a rise in severe infection cases was observed in people with obesity. A part of people with obesity exhibits certain markers on the surface of their immune cells, which are known to cause immunosuppression when present in high numbers, thus increasing the risk of developing infectious diseases.
Investigator teams found that after bariatric surgery and a calorie-restricted diet for weight loss, patients with obesity can improve the levels of these immunity-related markers. Moreover, the choice of foods consumed contributes to strengthening the immune system and immune functions of individuals, both directly by influencing inflammation and indirectly through the microbiota. However, to date, there are no dietary recommendations specifically designed to help people with obesity improve their immune response.
Therefore, this study aims to compare different dietary recommendations intended to improve immune status, with or without calorie restriction, during 3 months, in individuals with obesity (BMI ≥ 30 kg/m²) and impaired immunity. Over 6 months (3 months of nutritional intervention and 3 months of follow-up), investigators will collect extensive information through biological samples, measurements and questionnaires to compare the different dietary interventions studied and to understand the mechanisms behind the results obtained.
Beyond its metabolic consequences, obesity is associated with an increased risk of severe infectious diseases. Indeed, Obesity would be associated with immune remodeling, reduced microbial diversity, gut barrier dysfunction, and increased pro-inflammatory microbial species. These alterations can promote systemic inflammation and metabolic endotoxemia. Moreover, immune checkpoints, including the PD-1/PD-L1 pathway, are important regulators of immune responses and may also contribute to immune dysregulation in obesity.
Diet represents an important modulator of inflammation and immunity. The microbiome and the glycome may further mediate the effects of diet on immune function. Changes in microbial composition and host glycosylation can influence immune signaling and the activity of immune checkpoints.
Overall, the diet-microbiome-glycome axis may represent a key determinant of immune homeostasis in obesity. However, the effects of specific diets and nutrients on immune checkpoints remain insufficiently understood and require further clinical investigation.
In this clinical study, the investigator teams hypothesize that a nutritional intervention based on personalized dietary recommendations will improve the responses of markers associated with immunity (reduction in CD4+ cells and in the expression of immune checkpoint proteins on T cells, particularly PD-1) in individuals with obesity. The effects on immunity are thought to be mediated by changes in the gut microbiota and potentially by the immunoglycome, which should simultaneously lead to improvements in cardiometabolic health markers. These markers will also be monitored during this study.
The Nutrimmune clinical study is a controlled, randomized, open-label, parallel-group (3-arm), multicenter.
The investigators will recruit 168 volunteers (men or women) with moderate obesity (BMI between 30 and 40 kg/m²), aged 40 to 70 and at immune and metabolic inflammatory risk (hsCRP above 3 mg/L and dietary inflammatory index (E-DII)>0).
The intervention will consist of providing personalized nutritional advice through an app (called TOUVA developed by a private collaborator), which will offer participants appropriate meal plans each week. The nutritional advice will depend on the study arm to which the participant has been randomized.
Three nutritional interventions will be tested in parallel in this study:
During the study, participants will be seen for the first time during a screening visit, followed by three metabolic assessment visits: before starting the intervention, at 3 months into the nutritional intervention, and 3 months after the end of the intervention.
The primary endpoint will be the change in the percentage of CD4⁺ T cells expressing the immune checkpoint protein (ICP) PD-1 in PBMCs, measured from baseline to 3 months (end of the nutritional intervention).
The secondary endpoints included : immune and inflammatory phenotypes, microbiome and molecular mechanisms, cardiometabolic and physiological parameters, lifestyle and eating behaviour chang and acceptability, adherence and usability to the nutritional intervention.
This study would help advance scientific understanding of how dietary and personalized interventions can help improve markers associated with immunity in people with obesity and impaired immunity. In the public health goal to improve the care of people with obesity and impaired immunity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Low-grade inflammatory status, defined as:
General non-inclusion criteria:
Medical non-inclusion criteria:
Conditions that alter both inflammatory and immune profile and induce biases in results interpretation
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention will consist of providing personalized nutritional advice through an app called TOUVA, which will offer participants appropriate meal plans (according to their needs, food preferences and usual food consumption) each week during 3 months. The generated menu is based on food group distribution of the EAT- Lancet diet, except for oily fish, which will be set at two servings per week to ensure adequate omega-3 intake.
Other: Mixed test meal · Biological: Biological sampling · Behavioral: Questionnaires · Other: Balanced-immunity diet
Description: The intervention will consist of providing personalized nutritional advice through an app called TOUVA, which will offer participants appropriate meal plans (according to their needs, food preferences and usual food consumption) with a caloric restriction of 500 kcal/days (based on the evaluation of total energy requirements), each week during 3 months. The generated menu is based on food group distribution of the EAT- Lancet diet, except for oily fish, which will be set at two servings per week to ensure adequate omega-3 intake.
Other: Mixed test meal · Biological: Biological sampling · Behavioral: Questionnaires · Other: Caloric restriction · Other: Balanced-immunity diet
The intervention will consist of providing personalized nutritional advice through an app called TOUVA, which will offer participants appropriate meal plans, according to their needs, food preferences and usual food habits, each week during 3 months. The generated menu has a reduction of 500 kcal/day (based on the evaluation of total energy requirements). The calories reduction will be proportional across all food groups, except for fruits and vegetables, for which intake should remain unchanged.
Other: Mixed test meal · Biological: Biological sampling · Behavioral: Questionnaires · Other: Caloric restriction
A mixed test meal, rich in glucose and lipids will be served to the participant during baseline, 3 months and 6 months visits. The participant will have 10 minutes to eat it, and then blood will be sampled during the 4 hours following ingestion of the meal-test. The test meal must be consumed within 10 minutes in order to ensure standardized ingestion conditions between individuals and to limit biases linked to different ingestion times, which could subsequently alter the kinetics of biomarkers measured following meal ingestion. This will allow us to describe the postprandial excursions in glucose, triglycerides and insulin with indicators of the curve as amplitude, pick or time to return to baseline. These indicators are early markers of cardio-metabolic risk alterations. A biobanking of samples is also performed.
Changes in biological parameters will be assessed based on samples collected before the baseline, 3-month and 6-month visits (maximum 2 days before each visit) for feces, and during visits for blood and adipose tissue.
In order to assess some of the secondary outcomes, participants will be asked to fill in the following questionnaires : 3 24h-recall and validated Food Frequency questionnaire (FFQ), TEFQ, Baecke, Bristol, GSRS, SF12, IWQOL, PSS, PHQ-9, GSES, PSQI, MAUQ and CSQ-8.
Participants will be placed on a calorie-restricted diet with a reduction of 500 kcal/day (calculated based on total energy requirement) during 3 months. The calories reduction will be proportional across all food groups, except for fruits and vegetables, for which intake will remain unchanged.
The intervention consists of delivering the diet previously defined as the "Balanced-Immunity" diet in the form of meal plan and menus, accessible via TOUVA, a dedicated application during 3 months.
Comparison of changes in the percentage of PD-1⁺ CD4⁺ T cells in peripheral blood mononuclear cells between baseline and after 3 month of nutritional intervention
The first endpoint will be evaluated by calculating the change (Δ) in the percentage of PD-1⁺ CD4⁺ T cells between baseline and month 3 to determine the effect of each nutritional intervention. PBMCs will be isolated from peripheral blood samples locally in each center and then analyzed, centralized by flow cytometry to quantify the percentage of PD-1⁺ CD4⁺ T cells.
Time frame: Baseline and 3-months (after the nutritional intervention)
Comparison of changes in the percentage of PD-1⁺ CD4⁺ T cells in peripheral blood mononuclear cells between baseline and after 3 month of nutritional intervention and 3 month of follow-up
The endpoint will be evaluated by calculating the change (Δ) in the percentage of PD-1⁺ CD4⁺ T cells between baseline and month 6. Group comparisons will be based on these changes (Δ values) to determine the effect of each nutritional intervention. PBMCs will be isolated from peripheral blood samples locally in each center and then analyzed, centralized by flow cytometry to quantify the percentage of PD-1⁺ CD4⁺ T cells.
Time frame: Baseline and 6 months (after 3 months of nutritional intervention and 3 months of follow-up)
Comparison of immune cell phenotyping at baseline, month 3 and month 6 in peripheral blood mononuclear cells between the nutritional interventions
The endpoint will be evaluated by calculating the change (Δ) in cell phenotyping between baseline and month 3, baseline and month 6 and month 3 and month 6 to determine the effect of each nutritional intervention. PBMCs will be isolated from peripheral blood samples locally in each center and then analyzed, centralized by flow and mass cytometry.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Comparison of immune checkpoint proteins at baseline, month 3 and month 6 in peripheral blood mononuclear cells between the nutritional interventions
The endpoint will be evaluated by calculating the change (Δ) in immune checkpoint proteins between baseline and month 3 and baseline and month 6 to determine the effect of each nutritional intervention. PBMCs will be isolated from peripheral blood samples locally in each center and then analyzed, centralized by flow cytometry and mass cytometry
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Comparison of concentration of immunoglobulines G (IgG) in serum at baseline, month 3 and month 6 between the nutritional interventions
The endpoint will be evaluated by calculating the change (Δ) in the concentration of Immunoglobulines G in serum between baseline and month 3 and baseline and month 6. Group comparisons will be based on these changes (Δ values) to determine the effect of each nutritional intervention.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Comparison of cytokines and hsCRP at baseline, month 3 and month 6 in serum between the nutritional interventions
The endpoint will be evaluated by calculating the change (Δ) in the concentration of cytokines by Olink-multi-immune/inflammatory markers and hsCRP, between baseline and month 3 and baseline and month 6. Group comparisons will be based on these changes (Δ values) to determine the effect of each nutritional intervention.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Comparison of the ratio immunoglobulines A fecal/ immunoglobulines G fecal at baseline, month 3 and month 6 between the nutritional interventions
The endpoint will be evaluated by calculating the change (Δ) in the ratio IgA/IgG fecal by IgA and IgG binding pattern for microbiota between baseline and month 3 and baseline and month 6. Group comparisons will be based on these changes (Δ values) to determine the effect of each nutritional intervention.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Comparison of low-grade inflammation and immune-profile at baseline, month 3 and month 6 between the nutritional interventions
The endpoint will be evaluated by multiplex profiling of more than 750 circulating inflammatory and organ-specific proteins (Olink exploratory panels). Group comparisons will be based on the changes in the profile (Δ values) to determine the effect of each nutritional intervention.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Comparison of proteomics signatures linked to immune and organ-specific proteins at baseline, month 3 and month 6 between the nutritional interventions
The endpoint will be evaluated by multiplex profiling of more than 750 circulating inflammatory and organ-specific proteins (Olink exploratory panels). Group comparisons will be based on the changes in the profile (Δ values) to determine the effect of each nutritional intervention.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Comparison of glyco-immune checkpoint profile at baseline, month 3 and month 6 between the nutritional interventions
The glyco-immune checkpoint profiling in blood, PBMCs and adipose tissue will be evaluated with glycan technology and next-generation SUGAR-seq technology. Group comparisons will be based on the changes in the profile (Δ values) to determine the effect of each nutritional intervention.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Comparison of antigen stimulation and serology at baseline, month 3 and month 6 between the nutritional interventions
The outcome will be assessed from PBMC with co-culture test with CSA and nutriments in a subsample of participants from Lyon site. The following parameters will be studied: markers of helper and cytotoxic T-cell functions
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Comparison of gut microbiota composition, diversity and functional capacity at baseline, month 3 and month 6 between the nutritional interventions
Metagenomics will be performed by shotgun at baseline, month 3 and month 6 to assess and compare the nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Comparison of gut barrier integrity at baseline, month 3 and month 6 between the nutritional interventions
Gut barrier integrity will be assessed by the concentration of plasma lipopolysaccharide-binding protein (LBP) in plasma at baseline, month 3 and month 6 to assess and compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Comparison of gut permeability (fecal zonulin) at baseline, month 3 and month 6 between the nutritional interventions
Gut permability will be assessed by the concentration of fecal zonulin at baseline, month 3 and month 6 to assess and compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Comparison of short-chain fatty acids (SCFAs) profil at baseline, month 3 and month 6 between the nutritional interventions
SCFAs profil will be assessed by CGMS in plasma and in feces at baseline, month 3 and month 6 to assess and compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Comparison of metabolomics profil at baseline, month 3 and month 6 between the nutritional interventions
Target metabolomics will be done in plasma at baseline, month 3 and month 6 to assess metabolomics profil and compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Comparison of fecal pH at baseline, month 3 and month 6 between the nutritional interventions
Fecal pH will be assessed at baseline, month 3 and month 6 to compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Blood pressure at baseline, month 3 and month 6 between the nutritional interventions
Blood presure will be assessed at baseline, month 3 and month 6 to compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Resting heart rate at baseline, month 3 and month 6 between the nutritional interventions
Resting heart rate will be assessed at baseline, month 3 and month 6 to compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Body mass index at baseline, month 3 and month 6 between the nutritional interventions
Body mass index will be assessed at baseline, month 3 and month 6 to compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Waist circumferences, hip circumferences and waist/hip ratio at baseline, month 3 and month 6 between the nutritional interventions
Waist circumferences, hip circumferences and waist/hip ratio will be assessed at baseline, month 3 and month 6 to compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Body composition at baseline, month 3 and month 6 between the nutritional interventions
Body composition (lean and fat mass) will be assessed by bio-impedancemetry at baseline, month 3 and month 6 to compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Energy metabolism at baseline, month 3 and month 6 between the nutritional interventions
Energy metabolism (Resting Metabolic Rate) will be assessed by indirect calorimetry at baseline, month 3 and month 6 to compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Glycemia fasting at baseline, month 3 and month 6 between the nutritional interventions
Glycemia fasting will be assessed at baseline, month 3 and month 6 to compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Insulin fasting at baseline, month 3 and month 6 between the nutritional interventions
Insulin fasting will be assessed at baseline, month 3 and month 6 to compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Insulin resistance at baseline, month 3 and month 6 between the nutritional interventions
Insulin resistance will be assessed with the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) at baseline, month 3 and month 6 to compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Lipid profile fasting at baseline, month 3 and month 6 between the nutritional interventions
Lipid profile including: cholesterol, LDL, HDL, trigycerides, non-esterified fatty acids, and ApoB fasting will be assessed at baseline, month 3 and month 6 to compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Fatty acid profile at baseline, month 3 and month 6 between the nutritional interventions
Fatty acid profile will be assessed in adipose tissue at baseline, month 3 and month 6 to compare the three nutritional interventions in a subsample included in Lyon.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Liver health at baseline, month 3 and month 6 between the nutritional interventions
Liver health will be assessed with the level in plasma of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl transferase (GGT) :at baseline, month 3 and month 6 to compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Appetite-regulating hormones at baseline, month 3 and month 6 between the nutritional interventions
Level of adiponectin and leptin fasting hormones will be assessed at baseline, month 3 and month 6 to compare the three nutritional interventions.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Glucose kinetic after meal-test stimulation at baseline, month 3 and month 6 between the nutritional interventions
Glycemia will be assessed at t-30, t0, t15, t30, t45, t60, t90, t120, t180 and t240. The followings indicators will be calculated: maximum, minimum, times at peak or nadir, total and incremental AUCs (0-120, 120-240 and 0-240 min) during the postprandial period (meal-test).
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Insulin kinetic after meal-test stimulation at baseline, month 3 and month 6 between the nutritional interventions
Insulin will be assessed at t-30, t0, t15, t30, t45, t60, t90, t120, t180 and t240. The followings indicators will be calculated: maximum, minimum, times at peak or nadir, total and incremental AUCs (0-120, 120-240 and 0-240 min) during the postprandial period (meal-test).
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Triglycerides kinetic after meal-test stimulation at baseline, month 3 and month 6 between the nutritional interventions
Triglycerides will be assessed at t-30, t0, t60, t120 and t240. The followings indicators will be calculated: maximum, minimum, times at peak or nadir, total and incremental AUCs (0-120, 120-240 and 0-240 min) during the postprandial period (meal-test).
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Dietary intake of food groups at baseline, month 3 and month 6 between the nutritional interventions
Main food groups consumption will be assessed with 3 days of dietary records and validated Food Frequency Questionnaire (FFQ) filled in at baseline, month 3 and month 6.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Daily mean of calorie, macronutriment and micronutriments intakes at baseline, month 3 and month 6 between the nutritional interventions
Daily mean of calorie, macronutriment and micronutriments intakes will be assessed with 3 days of dietary records and validated Food Frequency Questionnaire (FFQ) filled in at baseline, month 3 and month 6.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Indexes of diet quality at baseline, month 3 and month 6 between the nutritional interventions
The Energy-adjusted Dietary Inflammatory Index (E-DII), alternative Healthy Eating Index (AHEI) and Dietary Approches to Stop Hypertension (DASH) will be assessed with a validated Food Frequency Questionnaire (FFQ) filled in at baseline, month 3 and month 6.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Modification of eating behaviour at baseline, month 3 and month 6 between the nutritional interventions
Modification of eating behaviour will be assessed with the three-factor eating questionnaire 21 (TFEQ-21), filled in at baseline, month 3 and month 6.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Modification of eating behaviour at baseline, month 3 and month 6 between the nutritional interventions
Modification of appetite will be assessed with visual analogue scales to range hunger, fullness and satiety fasting and at the end of meal test, at baseline, month 3 and month 6.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Modification of gastrointestinal tolerance at baseline, month 3 and month 6 between the nutritional interventions
Modification of gastrointestinal tolerance will be assessed with Bristol Stool Scale at baseline, month 3 and month 6.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Modification of gastrointestinal symptom at baseline, month 3 and month 6 between the nutritional interventions
Modification of gastrointestinal symptome will be assessed with the Gastrointestinal Symptom Rating Scale (GSRS) at baseline, month 3 and month 6.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Modification of quality of life at baseline, month 3 and month 6 between the nutritional interventions
Modification of quality of life will be assessed with the General quality of life questionnaire (SF-12) at baseline, month 3 and month 6.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Modification of impact of weight on quality of life at baseline, month 3 and month 6 between the nutritional interventions
Modification of impact of weight on quality of life will be assessed with the Impact of Weight on quality of Life (IWQOL) questionnaire at baseline, month 3 and month 6.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Modification of perceived stress at baseline, month 3 and month 6 between the nutritional interventions
Modification of perceived stress will be assessed with the Perceived Stress Scale (PSS) at baseline, month 3 and month 6.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Modification of self-efficacy at baseline, month 3 and month 6 between the nutritional interventions
Modification of self-efficacy will be assessed with general Stress-efficacy scale (GSES) at baseline, month 3 and month 6.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Modification of depresion symptoms at baseline, month 3 and month 6 between the nutritional interventions
Modification of depression symptoms will be assessed with Patient Health Questionnaire (PHQ-9) at baseline, month 3 and month 6.
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Physical activity and sedentary behavior at baseline, month 3 and month 6 between the nutritional interventions
Physical activity and sedentary behavior will be assessed by Baecke Physical Activity Questionnaire at baseline, month 3 and month 6
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Sleep duration and quality at baseline, month 3 and month 6 between the nutritional interventions
Sleep duration and quality will be assessed by Pittsburgh Sleep Quality Index (PSQI) at baseline, month 3 and month 6
Time frame: Between 1) baseline and month 3 (after the nutritional intervention) 2) baseline and month 6 (3 months of nutritional intervention and 3 months of follow-up) and 3) month 3 and month 6
Acceptability of the nutritional intervention by the application
Aceptability of the nutritional intervention by the application will be asses with the Client Satisfaction Questionnaire (CSQ-8), at the end of the intervention (month 3)
Time frame: After 3 month of nutritional intervention
Integration of the meal plan into daily life
Integration of the meal plan into daily life will be assessed with custom Likert-scale items daily during the intervention
Time frame: Between 1) baseline and month 3 (after the nutritional intervention)
Usuability to the nutritional intervention by the application
Usuability and user-friendliness of the mobile application will be assessed using the mHealth App Usability Questionnaire (MAUQ)
Time frame: At the end of nutritional intervention (month 3)
Plan to share: Undecided — Decision will be taken depending on local regulation at the end of the study
Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 24 months is close to that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut National de la Santé Et de la Recherche Médicale, France →